- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Zydus Lifesciences' FY26 revenues rose 17% to Rs. 27,150 Cr with 31.2% EBITDA. US FDA granted Saroglitazar NDA Priority Review, targeting Q4 FY27 launch. The company declared Re. 1 dividend and approved a Rs. 1,100 Cr share buyback, forecasting high-teen revenue growth for FY27.